Patents by Inventor Wenwu Zhai

Wenwu Zhai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • C3-BINDING AGENTS AND METHODS OF USE THEREOF
    Publication number: 20230382985
    Abstract: The present disclosure provides binding agents, such as antibodies (including single chain variable fragments), that specifically bind complement component C3, including human C3, compositions comprising same, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising same.
    Type: Application
    Filed: August 10, 2023
    Publication date: November 30, 2023
    Inventors: Dana Yen Mei Duey, Zhonghao Liu, Jie Tang, Yan Wang, Yiyuan Yin, Wenwu Zhai, Jared Martin Higbee
  • C3-binding agents and methods of use thereof
    Patent number: 11767359
    Abstract: The present disclosure provides binding agents, such as antibodies (including single chain variable fragments), that specifically bind complement component C3, including human C3, compositions comprising same, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising same.
    Type: Grant
    Filed: August 19, 2021
    Date of Patent: September 26, 2023
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Dana Yen Mei Duey, Zhonghao Liu, Jie Tang, Yan Wang, Yiyuan Yin, Wenwu Zhai, Jared Martin Higbee
  • Anti-interleukin-33 antibodies and uses thereof
    Patent number: 11725050
    Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: August 15, 2023
    Assignee: Genentech, Inc.
    Inventors: Philip E. Hass, Meredith Hazen, Yi-Chun Hsiao, Rajita Khosla, Gerald R. Nakamura, Dhaya Seshasayee, Menno Van Lookeren Campagne, Hongkang Xi, Wenwu Zhai, Jack Bevers, III, Nancy Chiang
  • Methods of lowering triglyceride levels with an ANGPTL8-binding antibody or antigen-binding fragment thereof
    Patent number: 11566067
    Abstract: The present disclosure provides binding agents, such as antibodies, that specifically bind Angiopoietin-like protein 8 (ANGPTL8), including human ANGPTL8, and methods of their use.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: January 31, 2023
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Chun Chu, Xunshan Ding, Zhonghao Liu, Yan Wang, Yiyuan Yin, Wenwu Zhai
  • C3-BINDING AGENTS AND METHODS OF USE THEREOF
    Publication number: 20220119508
    Abstract: The present disclosure provides binding agents, such as antibodies (including single chain variable fragments), that specifically bind complement component C3, including human C3, compositions comprising same, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising same.
    Type: Application
    Filed: August 19, 2021
    Publication date: April 21, 2022
    Inventors: Dana Yen Mei Duey, Zhonghao Liu, Jie Tang, Yan Wang, Yiyuan Yin, Wenwu Zhai, Jared Martin Higbee
  • Anti-C3 antibodies
    Patent number: 11136381
    Abstract: The present disclosure provides binding agents, such as antibodies (including single chain variable fragments), that specifically bind complement component C3, including human C3, compositions comprising same, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising same.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: October 5, 2021
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Dana Yen Mei Duey, Zhonghao Liu, Jie Tang, Yan Wang, Yiyuan Yin, Wenwu Zhai, Jared Martin Higbee
  • BISPECIFIC ANTIBODIES
    Publication number: 20210253741
    Abstract: The present disclosure relates to multispecific binding agents, in particular tetravalent bispecific antibodies, related polynucleotides, vectors, host cells, compositions, and methods of producing the binding agents.
    Type: Application
    Filed: July 2, 2019
    Publication date: August 19, 2021
    Inventors: Alan Kent Kutach, Wenyan Shen, Jie Tang, Wenwu Zhai
  • ANGPTL8-BINDING AGENTS AND METHODS OF USE THEREOF
    Publication number: 20210095014
    Abstract: The present disclosure provides binding agents, such as antibodies, that specifically bind Angiopoietin-like protein 8 (ANGPTL8), including human ANGPTL8, and methods of their use.
    Type: Application
    Filed: August 18, 2020
    Publication date: April 1, 2021
    Inventors: Chun Chu, Xunshan Ding, Zhonghao Liu, Yan Wang, Yiyuan Yin, Wenwu Zhai
  • ANTI-INTERLEUKIN-33 ANTIBODIES AND USES THEREOF
    Publication number: 20210002361
    Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.
    Type: Application
    Filed: June 16, 2020
    Publication date: January 7, 2021
    Inventors: Philip E. HASS, Meredith HAZEN, Yi-Chun HSIAO, Rajita KHOSLA, Gerald R. NAKAMURA, Dhaya SESHASAYEE, Menno VAN LOOKEREN CAMPAGNE, Hongkang XI, Wenwu ZHAI, Jack BEVERS, III, Nancy CHIANG
  • ANGPTL8-binding agents and methods of use thereof
    Patent number: 10774139
    Abstract: The present disclosure provides binding agents, such as antibodies, that specifically bind Angiopoietin-like protein 8 (ANGPTL8), including human ANGPTL8, and methods of their use.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: September 15, 2020
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Chun Chu, Xunshan Ding, Zhonghao Liu, Yan Wang, Yiyuan Yin, Wenwu Zhai
  • Anti-interleukin-33 antibodies and uses thereof
    Patent number: 10723795
    Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: July 28, 2020
    Assignee: Genentech, Inc.
    Inventors: Philip E. Hass, Meredith Hazen, Yi-Chun Hsiao, Rajita Khosla, Gerald R. Nakamura, Dhaya Seshasayee, Menno Van Lookeren Campagne, Hongkang Xi, Wenwu Zhai, Jack Bevers, III, Nancy Chiang
  • C3-BINDING AGENTS AND METHODS OF USE THEREOF
    Publication number: 20190322730
    Abstract: The present disclosure provides binding agents, such as antibodies (including single chain variable fragments), that specifically bind complement component C3, including human C3, compositions comprising same, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising same.
    Type: Application
    Filed: April 1, 2019
    Publication date: October 24, 2019
    Inventors: Dana Yen Mei Duey, Zhonghao Liu, Jie Tang, Yan Wang, Yiyuan Yin, Wenwu Zhai, Jared Martin Higbee
  • ANGPTL8-BINDING AGENTS AND METHODS OF USE THEREOF
    Publication number: 20190169281
    Abstract: The present disclosure provides binding agents, such as antibodies, that specifically bind Angiopoietin-like protein 8 (ANGPTL8), including human ANGPTL8, and methods of their use.
    Type: Application
    Filed: November 8, 2018
    Publication date: June 6, 2019
    Inventors: Chun Chu, Xunshan Ding, Zhonghao Liu, Yan Wang, Yiyuan Yin, Wenwu Zhai
  • ANTI-INTERLEUKIN-33 ANTIBODIES AND USES THEREOF
    Publication number: 20190092852
    Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.
    Type: Application
    Filed: August 31, 2018
    Publication date: March 28, 2019
    Inventors: Philip E. HASS, Meredith HAZEN, Yi-Chun HSIAO, Rajita KHOSLA, Gerald R. NAKAMURA, Dhaya SESHASAYEE, Menno VAN LOOKEREN CAMPAGNE, Hongkang XI, Wenwu ZHAI, Jack BEVERS, III, Nancy CHIANG
  • ANTAGONIST ANTI-IL-7 RECEPTOR ANTIBODIES AND METHODS
    Publication number: 20180327503
    Abstract: The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.
    Type: Application
    Filed: July 20, 2018
    Publication date: November 15, 2018
    Applicant: RINAT NEUROSCIENCE CORP.
    Inventors: CHIA-YANG LIN, LI-FEN LEE, WENWU ZHAI
  • Anti-interleukin-33 antibodies and uses thereof
    Patent number: 10093730
    Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: October 9, 2018
    Assignee: Genentech, Inc.
    Inventors: Philip E. Hass, Meredith Hazen, Yi-Chun Hsiao, Rajita Khosla, Gerald R. Nakamura, Dhaya Seshasayee, Menno Van Lookeren Campagne, Hongkang Xi, Wenwu Zhai, Jack Bevers, III, Nancy Chiang
  • Antagonist anti-IL-7 receptor antibodies and methods
    Patent number: 10059772
    Abstract: The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: August 28, 2018
    Assignee: RINAT NEUROSCIENCE CORP.
    Inventors: Chia-Yang Lin, Li-Fen Lee, Wenwu Zhai
  • Antibodies for Botulinum Neurotoxins
    Publication number: 20180208680
    Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Application
    Filed: January 12, 2018
    Publication date: July 26, 2018
    Inventors: James D. Marks, Yongfeng Fan, Jianlong Lou, Maria Consuelo Garcia Rodriguez, Shude Yan, Isin Nergiz Geren, Wenwu Zhai, Subhendu Chakraborti
  • Antibodies for Botulinum Neurotoxins
    Publication number: 20160229921
    Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Application
    Filed: December 11, 2015
    Publication date: August 11, 2016
    Inventors: James D. Marks, Yongfeng Fan, Jianlong Lou, Maria Consuelo Garcia Rodriguez, Shude Yan, Isin Nergiz Geren, Wenwu Zhai, Subhendu Chakraborti
  • ANTAGONIST ANTI-IL-7 RECEPTOR ANTIBODIES AND METHODS
    Publication number: 20160229917
    Abstract: The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.
    Type: Application
    Filed: April 22, 2016
    Publication date: August 11, 2016
    Applicant: RINAT NEUROSCIENCE CORP.
    Inventors: CHIA-YANG LIN, LI-FEN LEE, WENWU ZHAI